Russia pharmaceutical market · beneficiary changes since 24 February 2022 · updated 12.11.2026
Russia Pharma Market Map
Key High and Middle manufacturers, distributors and pharmacy chains: who owned them before 24 February 2022, who owns them now, and how control changed. Select a point or registry row to open a player card.
- Temporary management
- Foreign owner exit
- Reorganization / redomiciliation
- Transfer between Russian owners
- IPO / SPO
- No control change
- control changed
- unchanged / not established
- additional site
- in progress / initiative
- needs verification
Player registry (41)
Analytics
I2022
II2023
I2023
II2024
I2024
II2025
I2025
II2026
I2026
II
Legal mechanisms
- Temporary management (Decree No. 302 of 25 April 2023)Shareholder rights pass to the manager while ownership formally remains. Pharma: Nizhpharm (Decree No. 213 of 4 April 2025, Pharmirus LLC); Binnopharm Group request concerning Akrikhin (January 2026). Decree No. 604 of 24 August 2026 provides a separate basis for critical infrastructure; no pharmaceutical applications found.
- Foreign owner exit via the Government Commission (Decrees Nos. 81 and 618)Since October 2024: a discount of at least 60% to valuation and a budget contribution of at least 35%. Pharma: Takeda → Binergia, Reckitt Hygiene → Arnest. An alternative is transfer of distribution without sale of the legal entity (BMS, Eli Lilly → Swixx).
- Intragroup reorganization and redomiciliationNizhpharm → Nidda Lynx (did not prevent temporary management); Cyprus holding companies of Binnopharm Group → Kaliningrad special administrative region.
- IPO / SPONew share issues with a 7–10% free float while founders retain control: Promomed (July 2024), Ozon Pharmaceuticals (October 2024, SPO 2025).
- Transfers between Russian ownersR-Pharm → management (2022); Nanolek and Infamed K → partners of Pharmstandard (2025).
- Market levers without ownership changesCompulsory licences (semaglutide — Semavic became the No. 1 pharmacy brand); the “second extra” procurement exclusion rule for strategically important medicines from 1 July 2026; transition to EAEU registration rules from 1 January 2026.
Methodology
The 2025 market was RUB 3,343bn, including RUB 1,850bn in pharmacy medicines and RUB 1,030bn in the public sector; imports accounted for 53.2% by value (DSM Group). High comprises the top 20 corporations by value of pharmacy sales in 2025 (share ≥1.6%) and total-market leaders driven by public procurement (AstraZeneca, Roche, Novartis). Middle is the next tier (approximately 0.5–1.5% of the market), plus companies whose owners changed or that are exiting Russia. “Unchanged” means no change in control of the Russian business; operational restrictions (frozen investments and clinical trials) are not reflected. Points mark the main Russian facility or office; “approximate” indicates an office or region without an exact address. Source standard: a decree, issuer disclosure or at least two publications; otherwise marked “needs verification”. Media designated as undesirable organisations in Russia are not used. Foreign-agent materials carry a status label.
The registry is not a complete list of market participants.
Sources
Sources: 3 legal acts · 3 market reports · 31 media publications
Labelling. Materials of media outlets on the register of foreign agents are given with this status indicated (Federal Law No. 255-FZ of 14.07.2022). The status label follows the registers of the Russian Ministry of Justice, is for information only and does not assess the content. Foreign media publications and foreign primary sources (company press releases) are cited if the outlet has no special status in Russia. Titles of media publications are given in their original language.